Edit

Innovation & Translation

To actively engage in technology transfer and industry relations

EMBL’s strengths in research, services, and training make it a perfect industry partner and a breeding ground for research that sows the seeds for technology transfer. EMBL’s tech transfer arm, EMBLEM, is pivotal to that success.

Novel training formats, among other new activities, helps further develop an EMBL innovation culture, empower the next generation of EMBL fellows, and diversify current instruments for training and knowledge exchange between EMBL and industry partners.

Download the annual report summary

A snapshot of EMBL 2022 facts and figures

Translating fundamental science through industry collaboration

Sparking innovation with Danish BioInnovation Institute

A new formal agreement with BioInnovation Institute (BII) in Denmark will smooth transitions from fundamental science to innovation. BII selected an EMBL project to start Bio Studio, a programme to nurture world-class life science start-ups that benefit people and society.

BD Biosciences & EMBL help cell sorting enter new era

EMBL researchers, in collaboration with BD Biosciences, demonstrated a new technology that allows rapid image-based sorting of cells. The new technology represents a major upgrade to flow cytometry and has applications in diverse life science fields.

AlphaFold predicts most known protein structures

AlphaFold database grew exponentially, continuing to provide an unprecedented look at the 3D protein universe. DeepMind also visited EMBL Heidelberg to discuss current and future implications of artificial intelligence for life science research.

“This joint publication between EMBL and BD Biosciences is a fantastic example of how academia and industry can partner together to accelerate scientific and technological progress for the benefit of research and human health.”

— Eric Diebold, Worldwide Vice President of R&D for BD Biosciences, referring to the development of Image-enabled Cell Sorting (ICS), which uses BD’s novel CellViewTM Image Technology

Innovative public-private partnership building

Open Targets consortium welcomes new members

Pfizer and Genentech became the latest companies to join EMBL as Open Targets members. Open Targets is an innovative, large-scale public-private partnership that uses human genetics and genomics data to systematically identify and prioritise drug targets.

ERC grant helping realise 'SpaceM' commercial potential

A new grant will provide a way for fundamental metabolomics research to realise its commercial potential and promise in aiding drug development and precision medicine.

EMBL in Italy event held at GSK Vaccines in Siena

The GSK Vaccines site in Siena hosted an annual EMBL in Italy event. The hybrid meeting brought together industry leaders, representatives from biotech start-ups, data scientists, and researchers from academia.

“EMBL’s support in developing the AlphaFold Database was crucial; it significantly amplified the impact and reach of AlphaFold predictions across the global scientific community.”

– John Jumper, Senior Staff Research Scientist at DeepMind & AlphaFold Team Lead

Edit